Oct. 31 at 8:05 PM
$EDAP Tranche C – Additional Conditions Preceden
evidence, satisfactory to the Bank, that the Group has reached a level of EBITDA not lower than minus EUR 12,500,000 during the last 12
(twelve) months;
(k) evidence that that the Group has reached a level of revenues during the last 12 (twelve) months at least equal to EUR 69,000,000 (of which HIFU
equal to EUR 40,000,000);
(l) a Final Design Transfer document demonstrating achievement of manufacturing readiness for Focal One systems (including Focal One Plus and
next generation systems);
(m) a FocalPak volume growth chart comparing calendar year 2025 (CY25) and calendar year 2026 (CY26);
(n) a purchase order or signed operating lease agreement confirming the placement of at least one (1) Focal One system with Endometriosis capability in the European Union, to demonstrate the commercialization rollout of Focal One for Endometriosis treatment in Europe;
